Literature DB >> 19644022

Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology.

Katy Hanlon1, Lorna W Harries, Sian Ellard, Claudius E Rudin.   

Abstract

Chromosome 13q deletions are common in multiple myeloma and other cancers, demonstrating the importance of this region in tumorigenesis. We used a novel single nucleotide polymorphism (SNP)-based technique, digital SNP (dSNP), to identify loss of heterozygosity (LOH) at chromosome 13q in paraffin-embedded bone marrow biopsies from 22 patients with multiple myeloma. We analyzed heterozygous SNPs at 13q for the presence of allelic imbalances and examined the results by sequential probability ratio analysis. Where possible, dSNP results were confirmed by fluorescence in situ hybridization. Using dSNP, we identified 13q LOH in 16/18 (89%) (95% Confidence Interval; 65%, 99%) patients without the need for neoplastic cell enrichment. In 8/16 (50%) cases, either partial or interstitial patterns of LOH were observed. Both fluorescence in situ hybridization and dSNP data proved concordant in just 3/9 cases. Five of the six discrepancies showed LOH by dSNP occurring beyond the boundaries of the fluorescence in situ hybridization probes. Our findings show that dSNP represents a useful technique for the analysis of LOH in archival tissue with minimal infiltration of neoplastic cells. The high-resolution screening afforded by the dSNP technology allowed for the identification of complex chromosomal rearrangements, resulting in either partial or interstitial LOH. Digital SNP represents an attractive approach for the investigation of tumors not suitable for genomic-array analysis.

Entities:  

Mesh:

Year:  2009        PMID: 19644022      PMCID: PMC2729843          DOI: 10.2353/jmoldx.2009.090027

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  31 in total

1.  Delineation of the minimal region of loss at 13q14 in multiple myeloma.

Authors:  Manal O Elnenaei; Rifat A Hamoudi; John Swansbury; Alicja M Gruszka-Westwood; Vasantha Brito-Babapulle; Estella Matutes; Daniel Catovsky
Journal:  Genes Chromosomes Cancer       Date:  2003-01       Impact factor: 5.006

2.  Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma.

Authors:  Peter Liebisch; Andreas Viardot; Nicole Bassermann; Christiane Wendl; Katrin Roth; Hartmut Goldschmidt; Hermann Einsele; Christian Straka; Stephan Stilgenbauer; Hartmut Döhner; Martin Bentz
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

3.  Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.

Authors:  Hannes Kaufmann; Elisabeth Krömer; Thomas Nösslinger; Ansgar Weltermann; Jutta Ackermann; Regina Reisner; Marianne Bernhart; Johannes Drach
Journal:  Eur J Haematol       Date:  2003-09       Impact factor: 2.997

4.  Counting alleles to predict recurrence of early-stage colorectal cancers.

Authors:  Wei Zhou; Steven N Goodman; Gennaro Galizia; Eva Lieto; Francesca Ferraraccio; Carlo Pignatelli; Colin A Purdie; Juan Piris; Robert Morris; David J Harrison; Philip B Paty; Al Culliford; Katharine E Romans; Elizabeth A Montgomery; Michael A Choti; Kenneth W Kinzler; Bert Vogelstein
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

5.  Counting alleles reveals a connection between chromosome 18q loss and vascular invasion.

Authors:  W Zhou; G Galizia; E Lieto; S N Goodman; K E Romans; K W Kinzler; B Vogelstein; M A Choti; E A Montgomery
Journal:  Nat Biotechnol       Date:  2001-01       Impact factor: 54.908

6.  Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13.

Authors:  H Avet-Louseau; A Daviet; S Sauner; R Bataille
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

Review 7.  Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis.

Authors:  John T Reilly
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

8.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Authors:  Hervé Avet-Loiseau; Thierry Facon; Bernard Grosbois; Florence Magrangeas; Marie-José Rapp; Jean-Luc Harousseau; Stéphane Minvielle; Régis Bataille
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

9.  Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.

Authors:  Rafael Fonseca; David Harrington; Martin M Oken; Gordon W Dewald; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; Emily A Blood; S Vincent Rajkumar; Neil E Kay; Brian Van Ness; Philip R Greipp
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

10.  Interstitial deletions at the long arm of chromosome 13 may be as common as monosomies in multiple myeloma. A genotypic study.

Authors:  Josep F Nomdedéu; Adriana Lasa; Josep Ubeda; Giuseppe Saglio; Mar Bellido; Sílvia Casas; Maria J Carnicer; Anna Aventín; Anna Sureda; Jorge Sierra; Montserrat Baiget
Journal:  Haematologica       Date:  2002-08       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.